Empiric Treatment of Uncomplicated Cystitis Without Urine Testing
For uncomplicated cystitis in women, trimethoprim-sulfamethoxazole (160/800 mg twice daily for 3 days) is recommended as first-line empiric therapy when local resistance rates are <20%, with nitrofurantoin (100 mg twice daily for 5 days) or fosfomycin (3 g single dose) as excellent alternatives. 1
First-Line Treatment Options
Trimethoprim-Sulfamethoxazole (TMP-SMX)
- Dosage: 160/800 mg (double strength tablet) twice daily for 3 days 1, 2
- Efficacy: Early clinical cure rates of 90-100% and bacterial cure rates of 85-93% 1
- Key consideration: Only use when local resistance rates are <20%, as clinical cure rates drop significantly with resistant organisms (84% vs 41%) 1
Nitrofurantoin
- Dosage: 100 mg twice daily for 5 days 1
- Advantages: Maintains efficacy despite increasing resistance to other antibiotics 3
- Caution: Avoid in patients with renal impairment (GFR <30 ml/min) and in the third trimester of pregnancy 1
Fosfomycin Trometamol
- Dosage: 3 g single dose 1, 4
- Advantages: Convenient single-dose administration 4
- FDA indication: Specifically indicated for uncomplicated UTIs (acute cystitis) in women due to susceptible strains of E. coli and Enterococcus faecalis 4
Treatment Algorithm
Assess patient factors:
- If healthy, non-pregnant woman with typical symptoms (dysuria, frequency, urgency)
- No fever, flank pain, or other signs of upper UTI
- No structural/functional abnormalities of urinary tract
- No recent hospitalization or antibiotic use
Select antibiotic based on local resistance patterns:
Follow-up:
Special Considerations
- Fluoroquinolones: Though effective, should be reserved for more invasive infections due to resistance concerns and adverse effects 1, 5
- Beta-lactams: Less effective as empirical first-line therapy for uncomplicated cystitis 5
- Treatment duration: 3-day regimens are generally as effective as longer courses for uncomplicated cystitis, with fewer adverse events 6, 5
Common Pitfalls to Avoid
Using fluoroquinolones as first-line therapy: This contributes to resistance and exposes patients to unnecessary risks 1
Treating asymptomatic bacteriuria: This increases antibiotic resistance without clinical benefit, particularly in elderly patients 1
Inadequate assessment: Failing to rule out complicated UTI (pyelonephritis, structural abnormalities) before empiric treatment
Ignoring local resistance patterns: TMP-SMX efficacy drops significantly when used in areas with high resistance rates 1
Not considering patient-specific factors: Certain antibiotics (like nitrofurantoin) should be avoided in patients with renal impairment 1
Empiric treatment without urine testing is appropriate for typical, uncomplicated cystitis in women with classic symptoms, but patients with recurrent infections, treatment failures, or atypical presentations should undergo urine culture and sensitivity testing to guide therapy.